Electrolyte abnormalities and progressive renal failure in a cancer patient.
Schlondorff
J S
JS
Renal Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Harvard University, Boston, Massachusetts 02115, USA. jschlondorff@partners.org
Mendez
G P
GP
Rennke
H G
HG
Magee
C C
CC
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018906:Antineoplastic Agents, Alkylating / Q000633:toxicity; D001706:Biopsy; D003404:Creatinine / Q000097:blood; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003937:Diagnosis, Differential; D018450:Disease Progression; D000077143:Docetaxel; D004334:Drug Administration Schedule; D005354:Fibrosarcoma / Q000150:complications* / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D005500:Follow-Up Studies; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007069:Ifosfamide / Q000633:toxicity; D007249:Inflammation / Q000473:pathology; D007668:Kidney / Q000601:surgery; D007678:Kidney Glomerulus / Q000166:cytology / Q000648:ultrastructure; D007684:Kidney Tubules / Q000473:pathology; D008297:Male; D008875:Middle Aged; D051437:Renal Insufficiency / Q000378:metabolism*; D043823:Taxoids / Q000627:therapeutic use; D016896:Treatment Outcome; D014883:Water-Electrolyte Imbalance / Q000097:blood / Q000150:complications*; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D043823:Taxoids; D003841:Deoxycytidine; D000077143:Docetaxel; D003404:Creatinine; D007069:Ifosfamide; D000093542:Gemcitabine